隐蔽分组方法和过程:
|
这是一项随机、双盲、安慰剂对照研究。由非盲统计师产生随机序列者和对药物进行编号。非盲统计师不参与纳入受试者,也不宜参与以后的试验过程,不能参与结果的测量。
|
Process of allocation
concealment:
|
This is a randomized, double-blind, placebo-controlled study. Unblind statisticians generate random sequences and number the drugs. Unblinded statisticians are not involved in the inclusion of subjects, nor should they participate in the future trial process, and cannot participate in the measurement of results.
|
盲法:
|
患者以双盲的形式随机到试验组或对照组分别接受益肺散结方(颗粒)或匹配的安慰剂即无论研究者患者、医疗工作人员或辅助医疗工作人员均不知道所给予的药物。研究药物整个盲法以及匹配随机化编码都是由第三方数据统计中心人员完成。研究药物使用独立包装码进行标记,且匹配随机化编码。通过随机系统将研究药物分配给患者。研究药物编盲采用双盲方法。每个患者可能接受试验组药物,或者接受对照组药物。益肺散结方及其对应的安慰剂采用相同的包装以确保药物盲态。
|
Blinding:
|
Patients were randomized to double-blind to the experimental group or control group to receive Yifei Sanjie Recipe or matching placebo, respectively, that is, neither the investigator, the patient, the medical staff or the paramedical staff knew the medicines given. The entire blinding of the study drug and the matching randomization code was performed by the third-party data statistics center staff. The study drug was labeled with a separate packaging code, matching with a randomized code. Study drugs are distributed to patients through a random system. A double-blind approach was used to study drug blindness. Each patient may receive a test group drug or a control group drug. The Yifei Sanjie Recipe and its corresponding placebo are in the same package to ensure that the drug is blind.
|
揭盲或破盲原则和方法:
|
本试验采用一级揭盲方法,于数据全部输入数据库后,经盲态数据核查,数据库锁定,统计分析计划书确定后方可执行。揭盲时由非盲统计师将相应随机号所对应的真实组别信息发给项目统计师,由后者进行最终的统计分析并形成统计分析报告。
3.5.2紧急揭盲
试验准备阶段由非盲人员为每个随机号准备应急信封,以供紧急揭盲使用。由相应中心的主要研究者进行初步评估并判断是否需要紧急揭盲,当需要紧急揭盲时,由该中心主要研究者拆阅应急信封,获取相应组别信息。
|
Rules of uncover or
ceasing blinding:
|
This trial adopts the first-level unblinding method. After all the data is input into the database, it can be executed after blind data verification, database lock, and statistical analysis plan confirmed. When unblinding, the non-blind statistician will send the actual group information corresponding to the corresponding random number to the project statistician, who will perform the final statistical analysis and form a statistical analysis report.
Unblind urgently
In the test preparation phase, non-blind statisticians prepare emergency envelopes for each random number for emergency unblinding use. The primary investigator of the corresponding center will make a preliminary assessment and determine whether it is necessary to unblind urgently. When required to unblind urgently, the primary investigator will open the emergency envelope to obtain the corresponding group information.
|
统计方法名称:
|
统计分析
(1) 分析软件:用SAS9.4或以上版软件进行统计分析。
(2) 人口学信息:对各组入选病例的人口统计学及各有关特征作基线分析,以考察各组之间的可比性。
(3) 有效性分析:对各组的主要疗效指标及次要指标组间比较的统计分析分别基于MITT和PPS进行。
(4) 安全性分析:采用Fisher确切概率法χ2比较各组不良事件发生率及与研究药物有关的不良事件发生率,并列表描述本次试验所发生的不良事件、实验室检验结果在试验前后正常/异常的变化情况以及发生异常改变时与研究药物的关系。
(5) 统计分析方法:
本试验将采用SAS 9.4或以上版本软件进行统计分析。
定量指标的统计学描述将计算例数、均数、标准差、中位数、最小值和最大值(必要时计算25%分位数Q1、75%分位数Q3);分类指标的统计学描述将计算例数和百分率。对于时间-事件指标,采用Kaplan-Meier法进行统计描述。
(6) 主要终点分析
PFS 采用Clopper-Pearson确切法计算各组ORR的95%可信区间,计算出比数比(odds ratio)及其95%可信区间和p值。
(7) 次要终点分析
次要疗效终点为:OS、ORR、QoL。
采用Clopper-Pearson确切法计算各组ORR的95%可信区间,计算出比数比(odds ratio)及其95%可信区间和p值。
研究者评估的OS、PFS以统计描述为主,采用Kaplan-Meier法估算两个治疗组的中位OS、中位PFS及其95%置信区间,并通过绘制Kaplan-Meier曲线,以提供直观的对治疗组间差异的描述。组间比较将采用Log-Rank检验,组间风险比(HR)及其95%可信区间通过Cox比例风险模型获得。
QoL的组间比较采用考虑重复效应的方差分析(ANOVA)。
疗效指标为MDASI-LC。主要采用混合效应模型的重复测量方差分析方法进行组间比较和不同时间点差异的比较。第三周期(D63)时较基线的变化将采用协方差分析模型进行组间比较,模型中以较基线变化值为因变量,分组为组别变量,以基线为协变量,中心为固定因素。
描述每次访视时受试者的生活质量评分的变化情况。生活质量前后的变化值的组内比较采用配对t检验,组间比较采用ANOVA。
(8) 缺失数据处理
为了获得完整的数据集,研究人员将接受专业培训以避免丢失数据。经验丰富的研究人员将通过固定的短信和电话联系参与者。对于缺失数据,不进行填补。
(9) 期中分析
本研究不设立中期分析
(10) 安全性分析
按照SOC/PT汇总试验期间发生的各类不良事件的例数、发生率和例次。描述性统计实验室检查、生命体征、体格检查以及心电图检查等指标,描述治疗前后受试者安全性检查临床意义的改变,特别关注治疗前正常或异常无临床意义的受试者在用药后发生异常有临床意义的情况。
|
Statistical method:
|
Statistical analysis
(1) Software: we conduct statistical analysis with SAS9.4 or above.
(2) Demographic information: to baseline the demographic analysis and relevant characteristics of the selected cases in each group to investigate the comparability among each group.
(3) Effectiveness analysis: the statistical analysis of the main efficacy indicators and the secondary index groups was based on MITT and PPS, respectively.
(4) Safety analysis: Fisher exact probability of χ2 was used to compare the incidence of adverse events and the study drug, and describe the adverse events that occurred in this test, the normal/abnormal changes of laboratory test results, and the relationship with the study drug when abnormal changes occurred.
(5) Statistical analysis method:
This test will be statistically analyzed using SAS 9.4 or above.
(6) Main endpoint analysis: PFS uses the Clopper-Pearson exact method to calculate the 95% confidence interval of each ORR and calculate the OR (odds ratio) and its 95% confidence interval and p value.
(7) Secondary endpoint analysis
The secondary efficacy endpoint was: OS, ORR, QoL.
Clopper-Pearson's exact method calculates 95% confidence interval of each ORR, and ratio ratio (odds ratio) and its 95% confidence interval and p values are calculated.
The OS, PFS evaluated by the researchers was mainly statistical description, using Kaplan-Meier method to estimate the median OS, PFS, and 95% confidence interval of two treatment groups by drawing Kaplan-Meier curve, and Log-Rank test for intergroup comparison, and the intergroup risk ratio (HR) and its 95% confidence interval were obtained through the Cox proportional risk model.
The variance analysis of QoL (ANOVA).
The efficacy index is MDASI-LC. The repeated measurement variance analysis method of the hybrid effect model is mainly used to compare the differences between groups and different time points. Baseline variations in the third cycle (D63) with baseline variability values as dependent variables, grouped as group variables, baseline as covariates and center as fixed factors.
Describe the changes in the subject's quality of life score at each visit. Paired t-test is used for groups of changing values before and after quality of life and ANOVA. between groups
(8) Missing data processing
To obtain a complete dataset, the researchers will be professionally trained to avoid the loss of data. Experienced researchers will contact participants through fixed text messages and phone calls. No fill-in for the missing data.
(9) Interim phase analysis
An interim analysis is not setted in this study
(10) Safety analysis
Summarize the number, incidence, and number of adverse events occurring during the trial by SOC/PT. Descriptive statistical laboratory examination, vital signs, physical examination, and ECG examination, describing the clinical significance of subject safety examination before and after treatment, paying particular attention to normal or abnormal clinical significance before treatment.
|
试验完成后的统计结果(上传文件):
|
试验完成后统计分析结果将以学术论文形式公开发表。
|
Calculated Results ater
the Study Completed:
|
After the trial is completed, the statistical analysis results will be published in academic papers.
|
上传试验完成后的统计结果:
Statistical results after completion of the test file upload
|
|
是否公开试验完成后的统计结果:
Calculated Results after
the Study Completed(upload file):
|
公开
Public
|
全球唯一识别码:
UTN
|
|